OA11842A - Method for treating COPD. - Google Patents

Method for treating COPD. Download PDF

Info

Publication number
OA11842A
OA11842A OA1200100226A OA1200100226A OA11842A OA 11842 A OA11842 A OA 11842A OA 1200100226 A OA1200100226 A OA 1200100226A OA 1200100226 A OA1200100226 A OA 1200100226A OA 11842 A OA11842 A OA 11842A
Authority
OA
OAPI
Prior art keywords
rolipram
pde
ic5q
binds
ratio
Prior art date
Application number
OA1200100226A
Other languages
English (en)
Inventor
Siegfried B Christensen
Mary S Barnette
Theodore J Torphy
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of OA11842A publication Critical patent/OA11842A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
OA1200100226A 1999-03-01 2000-03-01 Method for treating COPD. OA11842A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12231599P 1999-03-01 1999-03-01

Publications (1)

Publication Number Publication Date
OA11842A true OA11842A (en) 2005-08-22

Family

ID=22401990

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100226A OA11842A (en) 1999-03-01 2000-03-01 Method for treating COPD.

Country Status (30)

Country Link
US (1) US6670394B1 (id)
EP (1) EP1156799A4 (id)
JP (1) JP2002538114A (id)
KR (1) KR20010102459A (id)
CN (1) CN1349403A (id)
AP (1) AP2001002248A0 (id)
AR (1) AR042369A1 (id)
AU (1) AU772583B2 (id)
BG (1) BG105953A (id)
BR (1) BR0008603A (id)
CA (1) CA2366036A1 (id)
CO (1) CO5160248A1 (id)
CZ (1) CZ20013149A3 (id)
DZ (1) DZ3019A1 (id)
EA (1) EA200100930A1 (id)
HK (1) HK1043935A1 (id)
HU (1) HUP0200288A3 (id)
ID (1) ID29888A (id)
IL (1) IL144992A0 (id)
MA (1) MA25522A1 (id)
NO (1) NO20014222L (id)
NZ (1) NZ513695A (id)
OA (1) OA11842A (id)
PE (1) PE20001505A1 (id)
PL (1) PL352816A1 (id)
SK (1) SK12372001A3 (id)
TR (1) TR200102514T2 (id)
UY (1) UY26040A1 (id)
WO (1) WO2000051598A1 (id)
ZA (1) ZA200107186B (id)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
US20040005995A1 (en) * 2001-07-26 2004-01-08 Edelson Jeffrey D Method for reducing exacerbations associated with copd
AR029984A1 (es) * 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
DK1606261T3 (da) 2003-03-10 2010-01-18 Nycomed Gmbh Hidtil ukendt fremgangsmåde til fremstilling af roflumilast
US20060205749A1 (en) * 2003-03-13 2006-09-14 Yuzuru Abe Remedy and/or preventive for lung diseases
JPWO2005056009A1 (ja) * 2003-12-12 2007-07-05 協和醗酵工業株式会社 肺疾患治療剤
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
AU2006224619B2 (en) 2005-03-16 2012-06-07 Takeda Gmbh Taste masked dosage form containing roflumilast
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225869B1 (en) * 1992-04-02 2007-11-28 Smithkline Beecham Corp Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them
US5605923A (en) * 1992-04-02 1997-02-25 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
EP1466598A3 (en) 1993-06-18 2007-06-27 Smithkline Beecham Corporation PDE-IV inhibitors
US5728705A (en) * 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
ATE154932T1 (de) * 1993-11-26 1997-07-15 Pfizer Isoxazolinverbindungen als entzündungshemmende mittel
UY25338A1 (es) 1998-01-07 2001-08-27 Smithkline Beecham Corp Método para tratar copd

Also Published As

Publication number Publication date
IL144992A0 (en) 2002-06-30
KR20010102459A (ko) 2001-11-15
AU3386900A (en) 2000-09-21
PL352816A1 (en) 2003-09-08
MA25522A1 (fr) 2002-10-01
AP2001002248A0 (en) 2001-09-30
ID29888A (id) 2001-10-18
AU772583B2 (en) 2004-04-29
EP1156799A4 (en) 2004-11-10
DZ3019A1 (fr) 2005-05-20
EA200100930A1 (ru) 2002-02-28
AR042369A1 (es) 2005-06-22
ZA200107186B (en) 2002-08-30
CA2366036A1 (en) 2000-09-08
BR0008603A (pt) 2001-12-26
HK1043935A1 (zh) 2002-10-04
NO20014222L (no) 2001-10-29
SK12372001A3 (sk) 2001-12-03
HUP0200288A3 (en) 2003-08-28
US6670394B1 (en) 2003-12-30
EP1156799A1 (en) 2001-11-28
CZ20013149A3 (cs) 2002-04-17
JP2002538114A (ja) 2002-11-12
CN1349403A (zh) 2002-05-15
BG105953A (bg) 2002-05-31
WO2000051598A1 (en) 2000-09-08
HUP0200288A2 (hu) 2002-05-29
CO5160248A1 (es) 2002-05-30
NZ513695A (en) 2001-09-28
PE20001505A1 (es) 2001-02-08
UY26040A1 (es) 2000-09-29
TR200102514T2 (tr) 2002-04-22
NO20014222D0 (no) 2001-08-31

Similar Documents

Publication Publication Date Title
US5998428A (en) Compounds and methods for treating PDE IV-related diseases
US6555576B1 (en) Method for treating exercise induced asthma
US6670394B1 (en) Method for treating COPD
EP0710109B1 (en) Method for identifying a PDE IV inhibitor
Gillin et al. Dose dependent inhibition of REM sleep in normal volunteers by biperiden, a muscarinic antagonist
Cartledge et al. Sildenafil
MXPA01008853A (en) Method for treating copd
Liu et al. Nifedipine for the treatment of chronic urticaria: a double-blind cross-over study
US20020115111A1 (en) Compounds
ZA200107187B (en) Method for treating exercise induced asthma.
HK1012255B (en) Method for identifying a pde iv inhibitor
Bousquet Rapid symptom relief in rhinitis
Gessner et al. The disulfiram-ethanol reaction
MXPA01008858A (en) Method for treating exercise induced asthma
Schwartz The long QT syndrome: a clinical counterpart of hERG mutations
Taylor Central nervous system stimulants
Dukes Antihistamines
House Cardiovascular effects of cocaine
HK1079117A1 (zh) 米那普仑的对映体(1s，2r)在药物制备上的用途
HK1079117B (en) Use of the enantiomer (1s, 2r) of milnacipran for the preparation of a medicament
HK1115329A1 (en) Use of (1s, 2r) enantiomer of milnacipran for the preparation of a medicine
HK1115329B (en) Use of (1s, 2r) enantiomer of milnacipran for the preparation of a medicine